- Category: Experimental HIV Drugs
- Published on Monday, 10 March 2014 00:00
- Written by Gregory Fowler
A combination of 2 antiretrovirals used as maintenance therapy for people with undetectable viral load -- the next-generation integrase inhibitor GSK1265744 and the NNRTI rilpivirine (Edurant) -- led to continued viral suppression in more than 80% of treated patients, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.
This study was done in preparation for a trial of long-acting injectable formulations of GSK1265744 (or GSK744 for short) and rilpivirine. These findings suggest that these drugs may be feasible for long-term maintenance therapy, though concerns remain about development of resistance under certain circumstances.
[David Margolis, CROI press conference, March 5, 2014]
D Margolis, C Brinson, J Eron, et al. 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 3-6. Abstract 91LB.